TIDMDPH

RNS Number : 8938S

Dechra Pharmaceuticals PLC

19 November 2021

19 November 2021

Dechra(R) Pharmaceuticals PLC

("Dechra" or "the Company")

Directorate Changes

Dechra is pleased to announce that following a comprehensive search process Alison Platt will be appointed as Chair with effect from 1 January 2022 . Tony Rice will step down from the Board on 31 December 2021.

Alison joined the Dechra Board as a Non-Executive Director in March 2020, she has extensive board experience gained in non-executive roles at, Bupa Arabia, Cable & Wireless, Skills for Health and the Foreign and Commonwealth Office. Alison is currently a Non-Executive Director at Tesco PLC, Spectrum Life and Chair of Legal & General Financial Advice.

In September 2021, the Company announced that Tony Rice, who has been Chairman for five years, wished to retire from the Board to devote more time to family and other business and charitable activities.

Dechra also announces today that Denise Goode, Non-Executive Director, has informed the Board that due to other commitments she has decided to tender her resignation and step down from the Board and leaves the Company on 30 November 2021.

Julian Heslop will re-assume the role of Audit Committee Chairman until a successor is appointed.

Ian Page, Chief Executive Officer, Dechra said:

"I am delighted that Alison has accepted the Chair following Tony's retirement at the end of the year. I look forward to working with Alison in her new role. Since joining us as a Non-Executive Director in 2020 Alison has gained a good understanding of Dechra and our culture. Her extensive leadership experience and skills will further enhance the team's capabilities. I would also like to acknowledge Tony's contribution to the development of the Group. We wish him all the best."

"I would like to thank Denise for her positive and professional contribution to the Group. I wish her all the very best for the future."

Alison Platt added:

"I am delighted to have been offered the position as Dechra's Chair and very much look forward to continuing to work with everyone at Dechra and continuing to build on the successful growth of the Company."

Commenting on the above changes Tony Rice, Dechra's Chairman added:

" It has been my privilege and pleasure to work with Ian, his management team and the Board and be part of its evolution, witnessing its growth, and the delivery of great products and services to our customers whilst returning strong returns to our shareholders."

"I would like to also congratulate Alison on her forthcoming appointment and to wish Denise every success in her future too."

 
 Enquiries: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive Officer        Office: +44 (0) 1606 814 730 
 e-mail: corporate.enquiries@dechra.com 
 
 TooleyStreet Communications Ltd 
 Fiona Tooley, Director                   Mobile: +44 (0) 7785 703 523 
  e-mail: fiona@tooleystreet.com           Office: +44 (0) 121 309 0099 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPGBGGUPGGRR

(END) Dow Jones Newswires

November 19, 2021 02:00 ET (07:00 GMT)

Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Dechra Pharmaceuticals
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Dechra Pharmaceuticals